Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment

Authors: Molina-Molina E, Krawczyk M, Stachowska E, et al.
Published in Clin Res Hepatol Gastroenterol 2019
A remarkable number of lean individuals in the United States suffer from NAFLD, likely due to distinct components of MetS, such as diabetes and/or hypertension.Indeed, as noticed in the Kangbuk Samsung Health Study, 16,279 non-obese patients with different grades of liver...
Read MoreNon-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment

Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism

Authors: Lefere, S and Tacke, F
Published in JHEP Reports
This article summarizes the (mainly preclinical) evidence of the role of adipose tissue inflammation and NAFLD via macrophages that play an important role in connecting adipose tissue inflammation to liver inflammation...
Read MoreMacrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism

Pioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated withDisease Recurrence

Authors: Bril F, Cusi K et al
Published in Diabetes 2019 Jun; 68 (Supplement 1)
ioglitazone (PIO) is effective for long-term treatment of patients with nonalcoholic steatohepatitis(NASH) with prediabetes or type 2 diabetes. It reduces liver fibrosis and increases adipose tissue insulin sensitivity...
Read MorePioglitazone Discontinuation in Patients with Nonalcoholic Steatohepatitis (NASH) Is Associated withDisease Recurrence

Natural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease

Authors: Luci C, Vieira E, Perchet T, et al.
Published in Front Immunol 2019;10:1192.
Lipid accumulation in the liver contributes to hepatocyte cell death and promotes liver injury. Local immune cells are activated either by Danger Associated Molecular Patterns (DAMPS) released by dead hepatocytes or by bacterial...
Read MoreNatural Killer Cells and Type 1 Innate Lymphoid Cells Are New Actors in Non-alcoholic Fatty Liver Disease

Modulation of Insulin Resistance in NAFLD

Authors: Khan, R. , Bril, F. , Cusi, K. and Newsome, P
Published in Hepatology. 2018 Dec 16 doi: 10.1002/hep.30429. [Epub ahead of print]
Since there is a close relationship between insulin resistance and NAFLD, modulation of insulin resistance has a considerable interest in the quest for effective treatments of NAFLD. This review article focuses on possible mechanisms...
Read MoreModulation of Insulin Resistance in NAFLD

Non-alcoholic fatty liver disease and the interface between primary and secondary care.

Authors: Emmanuel A Tsochatzis and Philip N Newsome
Published in in Lancet Gastroenterol Hepatol 2018; 3: 509–17.
The prevalence of Non-alcoholic fatty liver disease (NAFLD) is estimated to be 25–30% in unselected populations. Its prevalence is high but severity is low. However, many patients are now referred to hepatology departments...
Read MoreNon-alcoholic fatty liver disease and the interface between primary and secondary care.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES